Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Asian markets continue downhill ride
Wed, 30 Nov 09:30 am

Most Asian stock markets have opened the day on a weak note with stock markets in China (down 2.3%), Hong Kong (down 1.8%) and Taiwan (down 1.3%) leading the losses. However, markets in Malaysia (up 0.7%) and Indonesia (up 0.3%) are trading firm. The Indian stock market have opened the day in the red. Stocks in the consumer durables and capital goods space are leading the losses.

The BSE-Sensex is trading lower by 85 points (0.5%), while the NSE-Nifty is down by around 25 points (0.5%). Mid cap and small cap stocks are also trading in the red, with the BSE Mid Cap and BSE Small Cap indices down by 0.3% and 0.1% respectively. The rupee is trading at 52.15 to the US dollar.

Auto stocks have opened the day on a mixed note with Maruti Suzuki and Hero MotoCorp trading firm. However, Tata Motors and Ashok Leyland are facing selling pressure. As per a leading financial daily, India's leading passenger car manufacturer Maruti Suzuki has finalised a deal with Italian carmaker Fiat. As per the deal, Maruti will source up to 1 lakh diesel engines per year from Fiat. With this deal Maruti plans to increase the production of Swift hatchback from January 2012. A significant rise in petrol prices has boosted the demand diesel cars. While on the one hand the company is having a surplus capacity of petrol cars, it does not have enough capacity to meet the rising demand for diesel models. During the early part of November, 2011, Maruti hiked prices of diesel cars by up to Rs 10,000.

Pharma Stocks have opened the day on a weak note with Ranbaxy Laboratories, Aurobindo Pharma and Opto Circuit leading the losses. Pfizer's Lipitor, the largest selling drug in the world will lose its patent in the US today as the expiry is due. However, the big question is: Will Ranbaxy Laboratories be able to get a slice of that pie? Generic pharma company, Ranbaxy, has six-month exclusivity on the product, but with the company yet to resolve regulatory problems related to the manufacturing facilities in India, uncertainty remains over its exclusivity. Ranbaxy and its Japanese parent Daiichi Sankyo have in the past been confident of being able to launch their generic version of Lipitor in 2011. However, the company has not given any road map for the same yet.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Asian markets continue downhill ride". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.